Low-Dose Teclistamab Tested in Newly Diagnosed Multiple Myeloma
Tests low-dose teclistamab as follow-up treatment in adults with newly diagnosed multiple myeloma.
Plain-language title generated from the registry record
Registry title: Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
Key facts
- Where
- Monterrey, MexicoSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed multiple myeloma who have not had any treatment for it yet. Everyone gets low-dose teclistamab.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Newly diagnosed multiple myeloma. ECOG Performance Status Score of 0 or 1.
- Earlier treatment
- Cannot have had any earlier treatment for multiple myeloma. Cannot have had a stem cell transplant, either from a donor or from their own cells.
Main reasons for not taking part
- Earlier treatment for multiple myeloma
- Active central nervous system involvement or signs of meningeal involvement of multiple myeloma
- Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome or AL amyloidosis
- Hepatitis B or C virus infection, or human immunodeficiency virus (HIV) infection
- Active pregnancy before the first treatment
Read by machine on 12 November 2026.
Where in Mexico
- Hospital Universitario Dr. Jose E. GonzalezMonterrey, MexicoContact: David Gomez-Almaguer, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitario Dr. Jose E. Gonzalez
- Trial code
- NCT06758375
- Record updated
- 20 March 2025
- Original description
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.Read full original descriptionShow less
Low-dose Teclistamab As Consolidation in the First-line Treatment of Patients with Newly Diagnosed Multiple Myeloma.
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
Inclusion: ≥18 years of age; Newly diagnosed multiple myeloma; Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1; Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner; Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy.
Exclusion: History of previous treatment for MM; Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration; Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery; Presence of other concomitant malignancy; Women of childbearing age: active pregnancy prior to the first administration of treatment; Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis; Severe active infection secondary to viruses, bacteria or fungi; Pulmonary disease requiring supplemental oxygen; History of allogeneic or autologous hematopoietic cell transplantation; Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection; Cerebrovascular events or seizures in the last 6 months; Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage); Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months; Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma.